Quarterly ResultAug 3, 2026, 04:08 PM
Inspire Medical Q2 Revenue $200.6M; Raises FY26 Guidance
AI Summary
Inspire Medical Systems reported Q2 2026 financial results, with revenue decreasing 7.6% to $200.6 million, primarily due to U.S. revenue decline. Diluted EPS was $0.01, and adjusted diluted EPS was $0.14. The company raised its full-year 2026 revenue outlook to $835 million to $875 million and expects adjusted diluted EPS of $1.05 to $1.45. Additionally, Inspire announced a strategic growth plan, Project Horizon, involving $20 million to $25 million in restructuring charges to unlock $30 million in annualized growth investment capacity.
Key Highlights
- Q2 2026 revenue decreased 7.6% to $200.6 million, primarily due to a decline in U.S. revenue.
- Q2 2026 diluted EPS was $0.01; adjusted diluted EPS was $0.14.
- Q2 2026 operating cash flow was $23.2 million, up from $2.7 million in prior year.
- Full-year 2026 revenue outlook raised to $835 million to $875 million.
- Full-year 2026 adjusted operating margin expected to be 4% to 6%.
- Full-year 2026 adjusted diluted EPS expected to be $1.05 to $1.45.
- Strategic growth plan (Project Horizon) announced, targeting $20M-$25M pre-tax restructuring charges.
- Project Horizon aims to generate $30 million of annualized growth investment capacity.
Price Impact
More from INSP